Explore
Validate
Learn
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ALX-801-039-C100 - Provider product page
- Provider
- Enzo Life Sciences
- Proper citation
- Enzo Life Sciences Cat#ALX-801-039-C100, RRID:AB_2051913
- Product name
- MRP4 monoclonal antibody (M4I-80)
- Antibody type
- Monoclonal
- Antigen
- Recombinant protein fragment
- Reactivity
- Human, Mouse
- Host
- Rat
- Isotype
- IgG
- Antibody clone number
- M4I-80
- Vial size
- 100 μg
- Storage
- -20°C
Submitted references Increased serum bile acid concentration following low-dose chronic administration of thioacetamide in rats, as evidenced by metabolomic analysis.
Functionally overlapping roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate in vivo.
Impact of Abcc2 (Mrp2) and Abcc3 (Mrp3) on the in vivo elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate.
Mrp4 confers resistance to topotecan and protects the brain from chemotherapy.
Jeong ES, Kim G, Shin HJ, Park SM, Oh JH, Kim YB, Moon KS, Choi HK, Jeong J, Shin JG, Kim DH
Toxicology and applied pharmacology 2015 Oct 15;288(2):213-22
Toxicology and applied pharmacology 2015 Oct 15;288(2):213-22
Functionally overlapping roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate in vivo.
Vlaming ML, Pala Z, van Esch A, Wagenaar E, de Waart DR, van de Wetering K, van der Kruijssen CM, Oude Elferink RP, van Tellingen O, Schinkel AH
Clinical cancer research : an official journal of the American Association for Cancer Research 2009 May 1;15(9):3084-93
Clinical cancer research : an official journal of the American Association for Cancer Research 2009 May 1;15(9):3084-93
Impact of Abcc2 (Mrp2) and Abcc3 (Mrp3) on the in vivo elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate.
Vlaming ML, Pala Z, van Esch A, Wagenaar E, van Tellingen O, de Waart DR, Oude Elferink RP, van de Wetering K, Schinkel AH
Clinical cancer research : an official journal of the American Association for Cancer Research 2008 Dec 15;14(24):8152-60
Clinical cancer research : an official journal of the American Association for Cancer Research 2008 Dec 15;14(24):8152-60
Mrp4 confers resistance to topotecan and protects the brain from chemotherapy.
Leggas M, Adachi M, Scheffer GL, Sun D, Wielinga P, Du G, Mercer KE, Zhuang Y, Panetta JC, Johnston B, Scheper RJ, Stewart CF, Schuetz JD
Molecular and cellular biology 2004 Sep;24(17):7612-21
Molecular and cellular biology 2004 Sep;24(17):7612-21
No comments: Submit comment
No validations: Submit validation data